Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NWV
|
|||
| Former ID |
DNC011932
|
|||
| Drug Name |
1-(2-Ethoxy-phenyl)-piperazine
|
|||
| Synonyms |
1-(2-Ethoxyphenyl)piperazine; 13339-01-0; 1-(2-Ethoxy-phenyl)-piperazine; CHEMBL273923; Piperazine,1-(2-ethoxyphenyl)-; FBQIUSDQWOLCNY-UHFFFAOYSA-N; 1-(2-Ethoxyphenyl)piperazinium chloride; ehoxyphenylpiperazine; EINECS 236-389-0; AC1Q57PR; AC1Q37ZC; Oprea1_356570; labotest-bb lt00233165; 4(2-eth-oxyphenyl)piperazine; SCHEMBL255189; 2-ethoxy-1-piperazinylbenzene; 1-(2-ehoxyphenyl)-piperazine; N-(2-ethoxyphenyl)-piperazine; AC1L359U; 1-(2-ethoxyphenyl)-piperazine; N-(2-ethyoxyphenyl)-piperazine; CTK4B8518
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H18N2O
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1N2CCNCC2
|
|||
| InChI |
1S/C12H18N2O/c1-2-15-12-6-4-3-5-11(12)14-9-7-13-8-10-14/h3-6,13H,2,7-10H2,1H3
|
|||
| InChIKey |
FBQIUSDQWOLCNY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 13339-01-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Inhibitor | [1] |
| 5-HT 1D receptor (HTR1D) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.